<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05627466</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-546-6531</org_study_id>
    <nct_id>NCT05627466</nct_id>
  </id_info>
  <brief_title>US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Higher-risk Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>Expanded Access Program for Magrolimab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      The goal of this expanded access program is to provide rapid access to magrolimab&#xD;
      free-of-cost material, to treat patients in the United States suffering from relapsed or&#xD;
      refractory higher-risk myelodysplastic syndrome (MDS) or relapsed or refractory acute myeloid&#xD;
      leukemia (AML).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome</condition>
  <condition>Relapsed/Refractory Acute Myeloid Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magrolimab</intervention_name>
    <description>Administered intravenously</description>
    <other_name>GS-4721</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Individuals with relapsed or refractory myelodysplastic syndrome (MDS) defined&#xD;
             according to World Health Organization (WHO) 2016 classification with an Revised&#xD;
             International Prognostic Scoring System (IPSS-R) prognostic risk category of&#xD;
             intermediate, high, or very high risk who are refractory or relapsed, ineligible for&#xD;
             all known drugs with proven efficacy, and ineligible for existing clinical studies;&#xD;
             and the treating physician has assessed that the potential benefits of magrolimab&#xD;
             outweigh the risks.&#xD;
&#xD;
          -  Individuals with confirmation of acute myeloid leukemia (AML) according to WHO 2016&#xD;
             classification who are refractory or relapsed, ineligible for all known drugs with&#xD;
             proven efficacy, and ineligible for existing clinical studies; and the treating&#xD;
             physician has assessed that the potential benefits of magrolimab outweigh the risks.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status score of 0 to 3.&#xD;
&#xD;
          -  Treating physician plans to administer magrolimab in combination with&#xD;
             azacitadine/venetoclax or magrolimab in combination with azacitadine alone, following&#xD;
             the indication-specific combinations described in the protocol.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to magrolimab, azacitidine, venetoclax, their metabolites, or&#xD;
             formulation excipients, if applicable to planned treatment regimen.&#xD;
&#xD;
          -  Prior treatment with cluster of differentiation (CD)47 or signal regulatory protein&#xD;
             alpha (SIRPÎ±)-targeting agents.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bionical Emas</last_name>
    <email>patient.access@bionical-emas.com</email>
  </overall_contact_backup>
  <link>
    <url>http://www.yourpatientaccess.com</url>
    <description>Click on this link to request access through the Bionical Emas Patient Access Portal</description>
  </link>
  <link>
    <url>https://www.gileadclinicaltrials.com/study/?id=GS-US-546-6531</url>
    <description>Gilead Clinical Trials Website</description>
  </link>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>November 16, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2022</study_first_posted>
  <last_update_submitted>May 5, 2023</last_update_submitted>
  <last_update_submitted_qc>May 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magrolimab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

